US Stock Movement: Summit Therapeutics plunges on November 16 as FDA rejects approval, lung cancer drug launch faces obstacles, and insufficient evidence of survival benefit
Bitget异动解读2026/11/16 12:21Summit Therapeutics November 16 Sharp Decline Interpretation
Keywords: FDA rejection, lung cancer drug market obstacles, insufficient evidence of survival benefit
1. The US Food and Drug Administration (FDA) issued a Complete Response Letter after the November 14 target date, on November 15, rejecting the Biologics License Application for ivonescimab combined with platinum-based chemotherapy for the treatment of locally advanced or metastatic non-small cell lung cancer that has progressed after prior epidermal growth factor receptor tyrosine kinase inhibitor therapy, citing insufficient evidence to demonstrate that this therapy can help patients extend survival.
2. The company has not disclosed a timetable for resubmitting the application, nor has it specified what additional evidence it will provide to address the FDA's concerns. The prospects and timing for commercialization in the US market face uncertainty.
3. Partner Akeso announced on November 16 that it had received the Complete Response Letter and warned that the letter may lead to abnormal fluctuations in its share price.
(Disclaimer: This content is generated by AI technology based on publicly available information for summary purposes only. It is for reference only and does not constitute investment advice.)
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Buffett says he remains confident in Berkshire Hathaway
Buffett will donate Berkshire B shares to four family foundations
Pendle launches USDe fixed-term market, providing a new framework for on-chain credit
